Showing 1811-1820 of 3038 results for "".
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- Amydis Receives NIH Grant to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and Other Tauopathieshttps://modernod.com/news/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/2479481/Amydis announced a new phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH) to support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.<
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2021 Online Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-2021-online-conference/2479453/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 2021 Online Conference at www.nora2021.com. The conference will be available live online from Thursday, October 14 to Saturday, October 16, with select presenta
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- Retina Consultants of America Expands Into North Carolinahttps://modernod.com/news/retina-consultants-of-america-expands-into-north-carolina/2479446/Physician management services organization Retina Consultants of America (RCA) had added North Carolina Retina Associates (NC Retina Associates) to its national consortium. Terms of the deal were not disclosed. The addition of NC Retina Associates marks RCA’s first entry into the No
- Outlook Therapeutics Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-phase-3-norse-two-trial-of-lytenava-for-wet-amd/2479428/Outlook Therapeutics announced positive clinical and highly statistically significant topline results from its pivotal phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010/Lytenava (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). “We are de
- Oertli’s CataRhex 3 Device Now Equipped With Speep Pump Innovationhttps://modernod.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/Oertli Instrumente has expanded the CataRhex 3 to include the pump innovation, “SPEEP,” which is designed to provide more efficiency and precision in cataract surgery due to precise control of flow and vacuum. The CataRhex 3 is Oertli’s compact and portable surgical platf
- Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRShttps://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an i
- NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx to Promote Prescription Avenovahttps://modernod.com/news/novabay-pharmaceuticals-partners-with-harrow-healths-imprimisrx-to-promote-prescription-avenova/2479378/NovaBay Pharmaceuticals announced it has partnered with ImprimisRx to promote prescription Avenova. ImprimisRx, a wholly owned subsidiary of Harrow Health, will provide NovaBay with national sales, marketing, and distribution support for its FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bo